Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 101, Issue 3, Pages 283-290Publisher
WILEY
DOI: 10.1111/ejh.13131
Keywords
EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease
Categories
Funding
- National Science Foundation of China [81700173, 81730003]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), National Key R&D Program of China [2016YFC0902800]
- Innovation Capability Development Project of Jiangsu Province [BM2015004]
- Jiangsu Provincial Key Medical Center [YXZXA2016002]
Ask authors/readers for more resources
Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available